⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
FATE News
Fate Therapeutics, Inc.
Form 8-K
sec.gov
FATE
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
globenewswire.com
FATE
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
FATE
INDP
AMGN
NKTR
IBIO
TAK
SNY
INMB
CLMT
VERX
GTBP
BHVN
CHRS
GSK
BMY
MRK
ABBV
AZN
GILD
LLY
KYMR
REGN
SPRY
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
FATE
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
prnewswire.com
ARDX
FATE
MNKD
VRTX
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
globenewswire.com
MNKD
VRTX
FATE
ARDX
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
FATE
IPS Cell-Derived Platelets Market to Rise at 9.6% CAGR Through 2025-2031: Industry and Companies Analysis Featuring Megakaryon, Xueji Shengwu, Renerval, Help, Cynata, Fate, and Century Therapeutics - ResearchAndMarkets.com
businesswire.com
FATE
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
globenewswire.com
FATE
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
globenewswire.com
FATE